A Phase 1, First-in-human (FIH), Dose-finding and Expansion Study to Evaluate the Safety and Tolerability of XmAb808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors

Protocol No
XENCOR-XMAB808-01
Phase
I
Summary

The purpose of this study is to assess whether an investigational drug, called XmAb808, given
in combination with pembrolizumab, has any effects on your cancer, to determine the best dose of XmAb808 to treat your cancer, and if it is safe and well tolerated.

Description
A Phase 1 Study of XmAb808 in Select Advanced Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Colorectal, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Breast Cancers
ClinicalTrials.gov
go to website